Core B (Immunology Core) will provide standardized humoral immune monitoring assay services for evaluating antibody responses elicited by Ad26-Env/Gag/Pol prime, Env gp140 protein boost (Ad26/Env) vaccine regimens in the studies described in this IPCAVD program. Core B leadership will work closely with investigators responsible for the studies described in Project 1 and Project 2 and will participate actively in the scientific mission of the overall IPCAVD program. The primary goal of Core B is to provide the leadership and the technical expertise to ensure that all vaccine-induced humoral responses will be profiled in a standardized fashion and that the IPCAVD leadership is kept abreast of the latest developments in assessing vaccine-induced neutralizing and non-neutralizing humoral immunity, particularly in relation to their ability to prevent viral infection. To accomplish these goals, we propose the following three Specific Aims:
Specific Aim 1. To perform standardized neutralizing antibody (NAb) assays in both NHP and humans Specific Aim 2. To perform standardized non-neutralizing antibody assays in both NHP and humans Specific Aim 3. To integrate all antibody data into a Systems Serology profiling approach to define correlates of protective immunity

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Beth Israel Deaconess Medical Center
United States
Zip Code
Barouch, Dan H; Tomaka, Frank L; Wegmann, Frank et al. (2018) Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392:232-243
Badamchi-Zadeh, Alexander; Moynihan, Kelly D; Larocca, Rafael A et al. (2018) Combined HDAC and BET Inhibition Enhances Melanoma Vaccine Immunogenicity and Efficacy. J Immunol 201:2744-2752
Alter, Galit; Barouch, Dan (2018) Immune Correlate-Guided HIV Vaccine Design. Cell Host Microbe 24:25-33
Bricault, Christine A; Kovacs, James M; Badamchi-Zadeh, Alexander et al. (2018) Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs. J Virol :
Whitney, James B; Lim, So-Yon; Osuna, Christa E et al. (2018) Prevention of SIVmac251 reservoir seeding in rhesus monkeys by early antiretroviral therapy. Nat Commun 9:5429
Borducchi, Erica N; Liu, Jinyan; Nkolola, Joseph P et al. (2018) Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature 563:360-364
Barouch, Dan H (2018) A step forward for HIV vaccines. Lancet HIV 5:e338-e339